<DOC>
	<DOCNO>NCT01436214</DOCNO>
	<brief_summary>This study phase 1/2a , open label , dose escalation safety study APC-100 ( 2,2,5,7,8-Pentamethyl-6-chromanol ) men advance prostate cancer .</brief_summary>
	<brief_title>Dose-Escalation Safety Study APC-100 Treatment Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients histopathologically proven adenocarcinoma prostate Patients must progressive disease Patients must prior treatment bilateral orchiectomy androgen deprivation therapy LHRHblocker evidence treatment failure Patients treat secondary hormonal therapy Patients prior chemotherapy give castrateresistant prostate cancer Patients prior radiation therapy complete less 4 week prior enrollment Patients prior investigational therapy within 4 week treatment APC100 Evidence active second malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>